|
1
|
Lee AW, Ma BB, Ng WT and Chan AT:
Management of Nasopharyngeal Carcinoma: Current Practice and Future
Perspective. J Clin Oncol. 33:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang
LL, Liao XB, Xu HY, Chen L, Lai SZ, et al: Re-evaluation of 6th
edition of AJCC staging system for nasopharyngeal carcinoma and
proposed improvement based on magnetic resonance imaging. Int J
Radiat Oncol Biol Phys. 73:1326–1334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng L, Cao C, Cheng G, Hu Q and Chen X:
Cytomembranic PD-L1 expression in locoregionally advanced
nasopharyngeal carcinoma. OncoTargets Ther. 10:5483–5487. 2017.
View Article : Google Scholar
|
|
4
|
Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong
MH, Lu TX and Zhao C: Long-term treatment outcome of recurrent
nasopharyngeal carcinoma treated with salvage intensity modulated
radiotherapy. Eur J Cancer. 48:3422–3428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kong L, Wang L, Shen C, Hu C, Wang L and
Lu JJ: Salvage Intensity-Modulated Radiation Therapy (IMRT) for
Locally Recurrent Nasopharyngeal Cancer after Definitive IMRT: A
Novel Scenario of the Modern Era. Sci Rep. 6:328832016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen C, Fee W, Chen J, Chan C, Khong B,
Hara W, Goffinet D, Li D and Le QT: Salvage treatment for locally
recurrent nasopharyngeal carcinoma (NPC). Am J Clin Oncol.
37:327–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karam I, Huang SH, McNiven A, Su J, Xu W,
Waldron J, Bayley AJ, Kim J, Cho J, Ringash J, et al: Outcomes
after reirradiation for recurrent nasopharyngeal carcinoma: North
American experience. Head Neck. 38 (Suppl 1):E1102–E1109. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wulfkuhle JD, Liotta LA and Petricoin EF:
Proteomic applications for the early detection of cancer. Nat Rev
Cancer. 3:267–275. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dawson S-J, Tsui DWY, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sadar S, Kaspate D and Vyawahare N:
Protective effect of L-glutamine against diabetes-induced
nephropathy in experimental animal: Role of KIM-1, NGAL, TGF-β1,
and collagen-1. Ren Fail. 38:1483–1495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Papadopoulou-Marketou N, Margeli A,
Papassotiriou I, Chrousos GP, Kanaka-Gantenbein C and Wahlberg J:
NGAL as an Early Predictive Marker of Diabetic Nephropathy in
Children and Young Adults with Type 1 Diabetes Mellitus. J Diabetes
Res. 2017:75269192017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu F, Li N, Yang W, Wang R, Yu J and Wang
X: The expression analysis of NGAL and NGALR in clear cell renal
cell carcinoma. Gene. 676:269–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eilenberg W, Stojkovic S, Kaider A,
Piechota-Polanczyk A, Nanobachvili J, Domenig CM, Wojta J, Huk I,
Demyanets S and Neumayer C: Neutrophil Gelatinase Associated
Lipocalin (NGAL) for Identification of Unstable Plaques in Patients
with Asymptomatic Carotid Stenosis. Eur J Vasc Endovasc Surg.
57:768–777. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sueud T, Hadi NR, Abdulameer R, Jamil DA
and Al-Aubaidy HA: Assessing urinary levels of IL-18, NGAL and
albumin creatinine ratio in patients with diabetic nephropathy.
Diabetes Metab Syndr. 13:564–568. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oikonomou E, Tsalamandris S, Karlis D,
Siasos G, Chrysohoou C, Vogiatzi G, Dimitropoulos S, Charalambous
G, Kouskouni E and Tousoulis D: The association among biomarkers of
renal and heart function in patients with heart failure: The role
of NGAL. Biomarkers Med. 12:1323–1330. 2018. View Article : Google Scholar
|
|
16
|
Forster CS, Jackson E, Ma Q, Bennett M,
Shah SS and Goldstein SL: Predictive ability of NGAL in identifying
urinary tract infection in children with neurogenic bladders.
Pediatr Nephrol. 33:1365–1374. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hunsicker O, Feldheiser A, Weimann A,
Liehre D, Sehouli J, Wernecke KD and Spies C: Diagnostic value of
plasma NGAL and intraoperative diuresis for AKI after major
gynecological surgery in patients treated within an intraoperative
goal-directed hemodynamic algorithm: A substudy of a randomized
controlled trial. Medicine (Baltimore). 96:e73572017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang J, Li J, Li S, Li J, Yu C and Wei C:
Effect of Inhibiting NGAL Gene Expression on A549 Lung Cancer Cell
Migration and Invasion. Zhongguo Fei Ai Za Zhi. 18:187–192.
2015.(In Chinese). PubMed/NCBI
|
|
19
|
Wang PH, Ko JL, Yang SF and Lin LY:
Implication of human nonmetastatic clone 23 type 1 and its
downstream gene lipocalin 2 in metastasis and patients survival of
cancer of uterine cervix. Int J Cancer. 129:2380–2389. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Candido S, Maestro R, Polesel J, Catania
A, Maira F, Signorelli SS, McCubrey JA and Libra M: Roles of
neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.
Oncotarget. 5:1576–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song B, Zhang H, Jiang L, Chi Y, Tian J,
Du W, Yu B and Han Z: Down-regulation of lipocalin 2 suppresses the
growth of human lung adenocarcinoma through oxidative stress
involving Nrf2/HO-1 signaling. Acta Biochim Biophys Sin (Shanghai).
47:805–814. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung IH, Wu TI, Liao CJ, Hu JY, Lin YH,
Tai PJ, Lai CH and Lin KH: Overexpression of lipocalin 2 in human
cervical cancer enhances tumor invasion. Oncotarget. 7:11113–11126.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mongre RK, Sodhi SS, Sharma N, Ghosh M,
Kim JH, Kim N, Park YH, Shin YG, Kim SJ, Jiao ZJ, et al: Epigenetic
induction of epithelial to mesenchymal transition by LCN2 mediates
metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor
BRM270 in a xenograft model of lung adenocarcinoma. Int J Oncol.
48:84–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leung L, Radulovich N, Zhu CQ, Organ S,
Bandarchi B, Pintilie M, To C, Panchal D and Tsao MS: Lipocalin2
promotes invasion, tumorigenicity and gemcitabine resistance in
pancreatic ductal adenocarcinoma. PLoS One. 7:e466772012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Monisha J, Roy NK, Padmavathi G, Banik K,
Bordoloi D, Khwairakpam AM, Arfuso F, Chinnathambi A, Alahmadi TA,
Alharbi SA, et al: NGAL is downregulated in oral squamous cell
carcinoma and leads to increased survival, proliferation, migration
and chemoresistance. Cancers (Basel). 10:2282018. View Article : Google Scholar
|
|
26
|
Dertli R, Biyik M, Yolacan R,
Karakarcayildiz A, Keskin M, Kayar Y and Asil M: May Neutrophil
Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in
Patients with Hepatocellular Carcinoma (HCC)? J Gastrointest
Cancer. Nov 15–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Xu Q, Wang Y, Chen K and Li J: Serum
neutrophil gelatinase associated lipocalin (NGAL) as a biomarker
for predicting high dose methotrexate associated acute kidney
injury in children with acute lymphoblastic leukemia. Cancer
Chemother Pharmacol. 85:95–103. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han MY, Nie JW, Li YY, Zhu YZ and Wu G:
Downregulation of NGAL is required for the inhibition of
proliferation and the promotion of apoptosis of human gastric
cancer MGC-803 cells. Cell Physiol Biochem. 50:694–705. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pacifico F, Pisa L, Mellone S, Cillo M,
Lepore A and Leonardi A: NGAL promotes recruitment of tumor
infiltrating leukocytes. Oncotarget. 9:30761–30772. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hiromoto T, Noguchi K, Yamamura M, Zushi
Y, Segawa E, Takaoka K, Moridera K, Kishimoto H and Urade M:
Up-regulation of neutrophil gelatinase-associated lipocalin in oral
squamous cell carcinoma: Relation to cell differentiation. Oncol
Rep. 26:1415–1421. 2011.PubMed/NCBI
|
|
31
|
Lin CW, Yang WE, Lee WJ, Hua KT, Hsieh FK,
Hsiao M, Chen CC, Chow JM, Chen MK, Yang SF, et al: Lipocalin 2
prevents oral cancer metastasis through carbonic anhydrase IX
inhibition and is associated with favourable prognosis.
Carcinogenesis. 37:712–722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang S, Xin H, Li Y, Zhang D, Shi J, Yang
J and Chen X: Skimmin, a Coumarin from Hydrangea paniculata, Slows
down the Progression of Membranous Glomerulonephritis by
Anti-Inflammatory Effects and Inhibiting Immune Complex Deposition.
Evid Based Complement Alternat Med. 2013:8192962013.PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sen Z, Zhan XK, Jing J, Yi Z and Wanqi Z:
Chemosensitizing activities of cyclotides from Clitoria ternatea in
paclitaxel-resistant lung cancer cells. Oncol Lett. 5:641–644.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang S, Fu Y, Wang D and Wang J: Icotinib
enhances lung cancer cell radiosensitivity in vitro and in vivo by
inhibiting MAPK/ERK and AKT activation. Clin Exp Pharmacol Physiol.
45:969–977. 2018. View Article : Google Scholar
|
|
36
|
Zhang S, Yang J, Li H, Li Y, Liu Y, Zhang
D, Zhang F, Zhou W and Chen X: Skimmin, a coumarin, suppresses the
streptozotocin-induced diabetic nephropathy in wistar rats. Eur J
Pharmacol. 692:78–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xiao X, Yeoh BS and Vijay-Kumar M:
Lipocalin 2: An Emerging Player in Iron Homeostasis and
Inflammation. Annu Rev Nutr. 37:103–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lippi G, Meschi T, Nouvenne A, Mattiuzzi C
and Borghi L: Neutrophil gelatinase-associated lipocalin in cancer.
Adv Clin Chem. 64:179–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bauvois B and Susin SA: Revisiting
Neutrophil Gelatinase Associated Lipocalin (NGAL) in Cancer: Saint
or Sinner? Cancers (Basel). 102018.
|
|
40
|
Chakraborty S, Kaur S, Guha S and Batra
SK: The multifaceted roles of neutrophil gelatinase associated
lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta.
1826:129–169. 2012.PubMed/NCBI
|
|
41
|
Bouchet S and Bauvois B: Neutrophil
Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix
Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in
Leukaemias. Cancers (Basel). 6:796–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Valcourt U, Kowanetz M, Niimi H, Heldin CH
and Moustakas A: TGF-β and the Smad signaling pathway support
transcriptomic reprogramming during epithelial-mesenchymal cell
transition. Mol Biol Cell. 16:1987–2002. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vincent T, Neve EP, Johnson JR, Kukalev A,
Rojo F, Albanell J, Pietras K, Virtanen I, Philipson L, Leopold PL,
et al: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes
TGF-β mediated epithelial-mesenchymal transition. Nat Cell Biol.
11:943–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
